The role of the benchmark dose in a regulatory context.

The use of no observed adverse effect levels (NOAELs) as a way of interpreting toxicology studies carries a number of problems, and the benchmark dose (BMD), or its lower confidence limit have been proposed as potential replacements. In practice, the theoretical advantages of the BMD approach are often outweighed by the practical disadvantages posed in a regulatory context. Attempts to seek consensus for the routine use of BMD methodology tend to involve diluting its potential advantages as much as they address the disadvantages, resulting in a relatively complex interpolation tool that delivers little more than the NOAEL. It is time to recognise that the BMD will never entirely replace the NOAEL. The two methods can have complementary roles. The NOAEL is well suited as a routine simple summary of effects in toxicology studies, whilst the BMD can be a higher tier approach for the interpretation of the most critical studies in a regulatory data package.

[1]  M. Pieters,et al.  A Probabilistic Approach for Deriving Acceptable Human Intake Limits and Human Health Risks from Toxicological Studies: General Framework , 1998, Risk analysis : an official publication of the Society for Risk Analysis.

[2]  M Pelekis,et al.  Evaluation of subchronic toxicity data using the benchmark dose approach. , 2001, Regulatory toxicology and pharmacology : RTP.

[3]  Salomon Sand,et al.  The Benchmark Dose Method—Review of Available Models, and Recommendations for Application in Health Risk Assessment , 2003, Critical reviews in toxicology.

[4]  D Krewski,et al.  Procedures for calculating benchmark doses for health risk assessment. , 1998, Regulatory toxicology and pharmacology : RTP.

[5]  K S Crump,et al.  A new method for determining allowable daily intakes. , 1984, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[6]  L. Ryan,et al.  A semiparametric approach to risk assessment for quantitative outcomes. , 1996, Risk analysis : an official publication of the Society for Risk Analysis.

[7]  C J Portier,et al.  Characterizing Dose‐Response I: Critical Assessment of the Benchmark Dose Concept , 1998, Risk analysis : an official publication of the Society for Risk Analysis.

[8]  L Edler,et al.  Statistical models for low dose exposure. , 1998, Mutation research.

[9]  Kenny S. Crump,et al.  Calculation of Benchmark Doses from Continuous Data , 1995 .

[10]  H J Clewell,et al.  Investigation of the potential impact of benchmark dose and pharmacokinetic modeling in noncancer risk assessment. , 1997, Journal of toxicology and environmental health.

[11]  B. Manly Randomization, Bootstrap and Monte Carlo Methods in Biology , 2018 .

[12]  D. Jonker,et al.  The benchmark approach applied to a 28-day toxicity study with Rhodorsil Silane in rats. the impact of increasing the number of dose groups. , 2001, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[13]  D. Gaylor Quantalization of continuous data for benchmark dose estimation. , 1996, Regulatory toxicology and pharmacology : RTP.

[14]  Wout Slob,et al.  Dose-response modeling of continuous endpoints. , 2002, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  Paul M Schlosser,et al.  Benchmark dose risk assessment for formaldehyde using airflow modeling and a single-compartment, DNA-protein cross-link dosimetry model to estimate human equivalent doses. , 2003, Risk analysis : an official publication of the Society for Risk Analysis.

[16]  W Slikker,et al.  Risk assessment for neurotoxic effects. , 1990, Neurotoxicology.

[17]  R J Kavlock,et al.  Benchmark Dose Workshop: criteria for use of a benchmark dose to estimate a reference dose. , 1995, Regulatory toxicology and pharmacology : RTP.

[18]  Richard W. Lewis,et al.  Recognition of Adverse and Nonadverse Effects in Toxicity Studies , 2002, Toxicologic pathology.

[19]  Elaine M. Faustman Review of Noncancer Risk Assessment : Application of Benchmark Dose Methods Prepared for the Commission on Risk Assessment and Risk Management , 1996 .

[20]  Agneta Falk Filipsson,et al.  Comparison of available benchmark dose softwares and models using trichloroethylene as a model substance. , 2003, Regulatory toxicology and pharmacology : RTP.

[21]  Agneta Falk Filipsson,et al.  Benchmark Calculations in Risk Assessment Using Continuous Dose‐Response Information: The Influence of Variance and the Determination of a Cut‐Off Value , 2003, Risk analysis : an official publication of the Society for Risk Analysis.

[22]  J. Evans,et al.  Estimating Noncancer Uncertainty Factors: Are Ratios NOAELs Informative? , 1999, Risk analysis : an official publication of the Society for Risk Analysis.

[23]  J S Evans,et al.  Limitations to Empirical Extrapolation Studies: the Case of Bmd Ratios Limitations to Empirical Extrapolation Studies: the Case of Bmd Ratios By , 2000 .

[24]  F J Murray,et al.  A human health risk assessment of boron (boric acid and borax) in drinking water. , 1995, Regulatory toxicology and pharmacology : RTP.

[25]  K. Crump,et al.  Critical issues in benchmark calculations from continuous data. , 2002, Critical reviews in toxicology.